about us

EHP Investment Criteria


Ellington Healthcare Partners-About Ellington Healthcare Partners-Criteria Ellington Healthcare Partners-Contact

Ellington Healthcare Partners uses our expertise in regenerative medicine, stem cell biology, immunology, oncology, and nanotechnology to identify opportunities in the treatment of a broad range of diseases. For example in oncology, EHP will evaluate novel cancer therapies, immunotherapy, new chemotherapies, targeted therapy, management of adverse consequences, and quality of life improvement.

Read More

Ellington Healthcare Partners I, L.P. (“EHP”) is an early-stage Venture Capital Fund targeting innovative bio-pharma developments. The Fund is chaired by Tommy G. Thompson, former Secretary of the U.S. Department of Health and Human Services. Dr. Anthony “Tony” Tether, the former Director of Defense Advanced Research Project Agency (DARPA), is the Chair of the Investment Committee.

Read More

In the USA and the Americas:
Granville A. Ungerleider
+1 (646) 450-5587

Read More

Ellington Healthcare Partners seeks to be a lead or co-investor making commitments to early and mid-stage companies in investments in multi-stages up to $25 million. In the Bio-Pharma industry, this typically will characterize companies in Phase I or Phase II clinical trials.